|
業務類別
|
Biotechnology |
|
業務概覽
|
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its productoffering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others. |
| 公司地址
| 1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010 |
| 電話號碼
| +1 650 238-9600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.inva.com |
| 員工數量
| 159 |
| Ms. Marianne Zhen |
Chief Accounting Officer |
美元 420.00K |
24/03/2026 |
| Mr. Pavel Raifeld |
Director and Chief Executive Officer |
美元 600.00K |
24/03/2026 |
| Mr. Stephen Basso |
Chief Financial Officer and President of IST |
美元 475.00K |
24/03/2026 |
|
|
| Mr. Jules Haimovitz |
Independent Director |
24/03/2026 |
| Mr. Derek A. Small |
Independent Director |
24/03/2026 |
| Dr. Sarah J. Schlesinger, M.D. |
Independent Director |
24/03/2026 |
| Mr. Mark DiPaolo, Esq. |
Chairman of the Board |
24/03/2026 |
| Mr. Pavel Raifeld |
Director and Chief Executive Officer |
24/03/2026 |
|
|
|
|
